Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
|Videos|May 1, 2020
Special Issues for Patients With Bipolar Disorder Coping With COVID-19
Author(s)Melvin G. Mcinnis, MD, FRCPsych
Patients with bipolar disorder often find it difficult to maintain schedules and routines, all the more challenging with the COVID-19 pandemic. More in this video.
Advertisement
Patients with
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Yale trio-genomics study links hair-pulling and skin-picking to inherited OCD risk scores and rare DNA variants, hinting at shared brain pathways.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
2
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
3
New Adult ADHD Guidelines: What Resources Are Coming Soon
4
Brenipatide for Alcohol Use Disorder: Emerging Findings
5